Ruben A. Mesa, MD, discusses the future of JAK inhibitor therapy in myelofibrosis.
Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses the future of JAK inhibitor therapy in myelofibrosis.
The addition of more treatment options for myelofibrosis has been a benefit for patients and clinicians, Mesa says. Additionally, the FDA approval of a fourth JAK inhibitor, momelotinib, is anticipated in the near future, and it will bring its own distinct profile and complementary approach compared with other approved JAK inhibitors for myelofibrosis, Mesa explains.
In the long term, patients will be optimized on JAK inhibitor therapy based on characteristics, response, and dose, Mesa continues. An additional agent could also be implemented up-front or after a period of time, Mesa says.
More phase 3 trials in myelofibrosis are ongoing than ever before, and the outcomes of these studies will continue to help to guide treatment decisions, Mesa concludes.